# A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Source: https://onco.cc/trials/nct06385678/  
OnCo record `nct06385678` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab, Carboplatin, Cisplatin, Pemetrexed and Cetuximab in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT06385678 by Jiangsu HengRui Medicine Co., Ltd., with 47 participants enrolled, started 2024-07-05 and due to reach its primary completion in 2025-12. Interventions recorded: HRS-4642, Adebrelimab, SHR-9839, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection and Cetuximab Solution for Infusion.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06385678
- Phase: 1/2
- Setting: A Phase IB/II Clinical Study on the Safety, Tolerability and Efficacy of HRS-4642 in Combination With Anti-tumor Medication in Subjects With Advanced Solid Tumors
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT06385678: https://clinicaltrials.gov/study/NCT06385678

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06385678.json